The Wall Street Journal's Heather Mack covered the closing of Longevity Fund's new $22 million fund to support emerging therapies for age-related diseases. The venture-capital firm, run by single partner Laura Deming, 23, focuses on early-stage biotechnology companies working to increase the human healthspan. The newest fund has backed six companies to date.
"At just 23 years old, Laura Deming, Longevity Fund's founder, may have more of a textbook idea of aging than an experiential one. Like many people, Ms. Deming was just a child when she realized people could die from something called 'old age.' Unlike many people, she took that information and almost immediately began working on ways to change it," Mack wrote.
"At 12, she was conducting research at the University of California, San Francisco with renowned molecular biologist Cynthia Kenyon (now the vice president of aging research at Calico Labs)," Mack continued. "She headed to the Massachusetts Institute of Technology at 14 but later dropped out when she was awarded a Thiel Fellowship. That same year, the Longevity Fund was born."
Read the full story here.